YOLFTbeta
Sophia Genetics SA

Sophia Genetics SA

SOPH · NASDAQ · Healthcare / Health Information Services

8.21USD+0.35 (+4.45%)

Price History

Full chart

Market Stats

Previous Close7.86
Open7.87
Day Range7.51 – 8.32
52-Week Range3.75 – 8.98
Volume623.07K
Market Cap709.97M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.16
Dividend Yield0.00%
Beta0.98
50-Day Avg7.43
200-Day Avg5.59

About

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Ross Jordan Muken B.Sc.
  • Employees415
  • HeadquartersLa PiEce 12, Rolle, Switzerland, 1180, USA
  • Websitehttps://www.sophiagenetics.com

Leadership

  • Dr. Jurgi Camblong M.B.A., Ph.D.Co-Founder & Executive Chairman · b. 1978
  • Mr. Ross Jordan Muken B.Sc.CEO & Director · b. 1980
  • Mr. George A. Cardoza M.B.A.Executive VP & CFO · b. 1962
  • Mr. Abhimanyu VermaEVP & Chief Technology Officer
  • Dr. Zhenyu Xu Ph.D.Executive VP & Chief Scientific Officer · b. 1983
  • Kellen SangerHead of Strategy and Investor Relations
  • Mr. Daan van Well L.L.M., M.B.A.Executive VP and Chief Legal & Compliance Officer · b. 1975
  • Mr. Kevin PuylaertSVP & Chief Sales Officer
  • Ms. Manuela Da Silva Valente B.A.Executive VP & Chief People Officer · b. 1971
  • Dr. Philippe Menu M.B.A., M.D., Ph.D.Executive VP, Chief Medical Officer & Chief Product Officer · b. 1982

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue25.36M28.40M40.45M47.56M62.37M65.17M77.27M
Growth (%)-+11.98%+42.43%+17.58%+31.14%+4.49%+18.56%
Cost of Revenue7.53M10.71M15.23M16.31M19.46M21.24M29.46M
Gross Profit17.83M17.69M25.22M31.25M42.91M43.94M47.81M
Gross Margin70.30%62.29%62.35%65.71%68.80%67.42%61.88%
Operating Expense50.12M55.08M96.71M119.08M117.74M110.50M118.74M
Operating Income-32.29M-37.39M-71.49M-87.82M-74.83M-66.57M-70.92M
Operating Margin-127.30%-131.64%-176.73%-184.66%-119.97%-102.14%-91.79%
EBITDA-30.74M-37.99M-69.24M-81.38M-69.57M-50.76M-64.40M
EBITDA Margin-121.21%-133.79%-171.17%-171.10%-111.54%-77.89%-83.35%
Net Income-33.79M-39.34M-73.67M-87.45M-78.98M-62.49M-79.00M
Net Income Margin-133.23%-138.52%-182.14%-183.87%-126.63%-95.89%-102.24%
R&D15.02M18.59M26.58M35.37M36.97M34.37M33.57M
R&D as % of Total Revenue59.21%65.45%65.71%74.37%59.27%52.73%43.44%
Interest Expense976.00K840.00K658.00K639.00K588.00K1.91M4.55M
Interest Expense % of Total Revenue3.85%2.96%1.63%1.34%0.94%2.94%5.89%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets76.62M51.66M132.12M320.17M243.84M206.16M155.31M163.46M
Total Liabilities21.80M29.40M31.61M44.77M43.71M54.71M58.82M116.31M
Total Equity54.82M22.25M100.51M275.40M200.13M151.44M96.49M47.15M
Cash53.91M18.07M74.63M192.96M161.31M123.25M80.23M70.29M
Total Debt9.21M8.46M7.25M13.06M16.74M18.60M30.03M63.02M
Net Debt-44.69M-9.61M-67.38M-179.90M-144.56M-104.65M-50.20M-7.27M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.68M-31.73M-57.94M-70.09M-48.58M-42.82M-38.01M
Investing Cash Flow-3.03M-24.32M-56.93M41.97M8.32M-8.18M-10.51M
Financing Cash Flow-1.02M107.05M237.77M-1.57M-2.82M11.59M34.13M
Capital Expenditure3.03M3.20M6.67M10.38M9.23M8.18M574.00K
Free Cash Flow-34.71M-34.93M-64.61M-80.47M-57.80M-51.00M-38.59M
Dividends Paid----000
FCF to OCF109.57%110.10%111.51%114.81%118.99%119.09%101.51%
Dividend Paid to FCF----0.00%0.00%0.00%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Sep 9, 2021Nov 10, 2021Mar 15, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 7, 2023May 9, 2023Aug 8, 2023Nov 7, 2023Mar 5, 2024May 7, 2024Aug 6, 2024Nov 5, 2024Mar 3, 2025May 6, 2025Aug 5, 2025Nov 4, 2025Mar 3, 2026May 5, 2026Aug 4, 2026Nov 3, 2026
EPS Estimate0.000.000.00-0.39-0.37-0.36-0.30-0.39-0.36-0.36-0.28-0.26-0.24-0.27-0.21-0.20-0.18-0.15-0.19-0.17-0.20-0.22-0.24-0.15-0.13
EPS Actual-0.27-0.26-0.26-0.31-0.30-0.28-0.34-0.31-0.36-0.22-0.26-0.25-0.14-0.37-0.14-0.15-0.21-0.12-0.18-0.25-0.20-0.17-0.19-0.26-
Surprise---20.51%18.92%22.22%-13.33%20.51%0.00%38.89%7.14%3.85%41.67%-37.04%33.33%25.00%-16.67%20.07%5.26%-47.06%0.00%22.41%20.83%-73.33%-
Timing---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap709.97M
Enterprise Value646.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.24
Price / Book8.33
EPS-1.16
Book Value0.976
Revenue (TTM)86.17M
Gross Profit (TTM)57.41M
EBITDA-71.75M
Profit Margin-93.86%
Operating Margin-86.03%
Return on Equity-101.22%
Return on Assets-24.52%
Shares Outstanding85.13M
Shares Float65.38M
Beta0.98
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 9.75
  • Strong Buy
    4
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
62.26%
Insiders
6.78%
Retail / Other
30.96%

Top Institutional Holders

  • Generation Investment Management LLP
    6.79M7.98%
  • AIGH Capital Management, LLC
    3.95M4.64%
  • Akre Capital Management, LLC
    3.72M4.37%
  • Principal Financial Group Inc
    2.36M2.78%
  • Banque Pictet & Cie SA
    2.21M2.59%
  • Royce & Associates, LP
    1.82M2.13%
  • Soleus Capital Management, L.P.
    1.56M1.84%
  • Alta Wealth Advisors LLC
    1.41M1.66%
  • Kennedy Capital Management Inc
    917.98K1.08%
  • Archon Capital Management LLC
    691.41K0.81%
  • Essex Investment Management Company, LLC
    663.43K0.78%
  • Ensign Peak Advisors Inc
    444.95K0.52%
  • Hodges Capital Management Inc
    409.07K0.48%
  • SEI Investments Co
    357.89K0.42%

Top Fund Holders

  • Columbia Small Cap Growth Inst
    1.24M1.46%
  • Royce Micro-Cap Trust
    897.63K1.05%
  • Principal SmallCap R5
    878.50K1.03%
  • FTGF RY US SmCp Opp A USD Dis(A)
    710.75K0.83%
  • Royce Small-Cap Opportunity Invmt
    660.41K0.78%
  • Royce Micro-Cap Invmt
    377.82K0.44%